- Home
- GPI vs ARQT Comparison
GPI vs ARQT Comparison
Compare GPI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GPI | ARQT |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GPI | ARQT |
|---|---|---|
| Price | $240.26 | $28.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $346.42 | $37.00 |
| AVG Volume (30 Days) | 268.2K | ★ 2.9M |
| Earning Date | 10-28-2026 | 10-27-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 19.50 | 0.03 |
| Revenue | ★ $11,123,721,000.00 | $376,072,000.00 |
| Revenue This Year | N/A | $42.98 |
| Revenue Next Year | $5.58 | $27.75 |
| P/E Ratio | ★ $11.71 | $879.67 |
| Revenue Growth | 2.17 | ★ 91.34 |
| 52 Week Low | $225.51 | $19.30 |
| 52 Week High | $461.27 | $31.77 |
Technical Indicators
Market Signals| Indicator | GPI | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 65.57 |
| Support Level | N/A | $24.91 |
| Resistance Level | $257.07 | $30.30 |
| Average True Range (ATR) | 9.17 | 1.16 |
| MACD | 0.15 | 0.23 |
| Stochastic Oscillator | 44.57 | 96.24 |
Price Performance
Historical ComparisonAbout GPI Group 1 Automotive Inc.
Group 1 owns and operates 32 collision centers and over 250 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 106 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.